Case-Based Roundtable Meetings Spotlight: April 2, 2023

During a Targeted Oncology™ Case-Based Roundtable™ event, Cyrus Khan, MD, discussed the case of a patient with relapsed/refractory diffuse large B-cell lymphoma who was referred for chimeric antigen receptor T-cell therapy and was place on a waiting list for treatment.

During a Targeted Oncology™ Case-Based Roundtable™ event, Paul D. DiSilvestro, MD, discussed the key trials supporting the use of PARP inhibitor maintenance therapy for patients with advanced ovarian cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Rafael Fonseca, MD, discussed the treatment paradigm for relapsed/refractory multiple myeloma and how the BCMA target now plays a role.

During a Targeted Oncology™ Case-Based Roundtable™ event, Richard Kim, MD, discussed regimens for biliary tract cancers including the results of the TOPAZ-1 trial of additional durvalumab.

During a Targeted Oncology™ Case-Based Roundtable™ event, Corey J. Langer, MD, discussed the EMPOWER Lung-3 and POSEIDON trials of immunotherapy options in patients with non–small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Amit Singal, MD, discussed next steps for a patient with a LI-RADS 5 hepatic mass who has cirrhosis, Crohn disease, and a history of variceal bleeding.

During a Targeted Oncology™ Case-Based Roundtable™ event, Yousef Zakharia, MD, discussed next-line therapy for a patient with metastatic castration-resistant prostate cancer who has received docetaxel and an androgen receptor–targeted therapy.

During a Targeted Oncology™ Case-Based Roundtable™ event, Douglas W. Sborov, MD, MS, discussed possible therapy options for a patient who relapsed after receiving bortezomib, lenalidomide, and dexamethasone followed by autologous stem cell transplant.

During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan Abbas, MD, discussed data on therapies for a patient with polycythemia vera who did not adequately respond to hydroxyurea.

During a live, virtual event, Thomas Hutson, DO, PharmD, discussed the case of a 54-year-old man with a history of metastatic renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, J. Nicholas Bodor, MD, PhD, MPH, discussed the CheckMate 9LA regimen of nivolumab and ipilimumab plus chemotherapy for patients with advanced squamous non–small cell lung cancer.